{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:08:05Z","timestamp":1786118885432,"version":"build-2736575974"},"reference-count":0,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Opinion in Oncology"],"published-print":{"date-parts":[[1995,5]]},"DOI":"10.1097\/00001622-199505000-00014","type":"journal-article","created":{"date-parts":[[2007,12,12]],"date-time":"2007-12-12T03:25:02Z","timestamp":1197429902000},"page":"281-291","source":"Crossref","is-referenced-by-count":11,"title":["Prostate cancer in the era of prostate-specific antigen"],"prefix":"10.1097","volume":"7","author":[{"given":"Howard I.","family":"Scher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Fossa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","container-title":["Current Opinion in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00001622-199505000-00014","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T16:57:09Z","timestamp":1786035429000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00001622-199505000-00014"}},"subtitle":[""],"short-title":[],"issued":{"date-parts":[[1995,5]]},"references-count":0,"journal-issue":{"issue":"3"},"URL":"https:\/\/doi.org\/10.1097\/00001622-199505000-00014","relation":{},"ISSN":["1040-8746"],"issn-type":[{"value":"1040-8746","type":"print"}],"subject":[],"published":{"date-parts":[[1995,5]]}}}